Fibromyalgia: Why vagal nerve stimulation is gaining traction

Written by The Life Science Feed Editorial Team · Published 11 September 2026 · Edited by William Lopes

> Fibromyalgia remains a debilitating chronic pain condition, often resistant to conventional pharmacotherapy and leaving many patients with persistent, widespread pain and fatigue. Current management strategies frequently fall short, highlighting a significant unmet need for effective, non-pharmacological interventions. A recent review of non-invasive neuromodulation (NINM) methods suggests that nerve stimulation may offer a viable path forward for these patients.1

KEY TAKEAWAYS

- The Pivot: Non-invasive neuromodulation, particularly transcutaneous vagal nerve stimulation, is emerging as a credible therapeutic option for chronic pain conditions like fibromyalgia.
- The Data: While specific human trial data for fibromyalgia is still developing, preclinical models show transcutaneous vagal nerve stimulation improves post-traumatic osteoarthritis pain in mice, indicating a potential mechanism for broader chronic pain relief.2
- The Action: Clinicians should consider the growing evidence for neuromodulation as an adjunctive therapy, particularly as wearable device technology advances, for patients who have exhausted traditional pain management options.

Fibromyalgia is characterised by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. The aetiology remains poorly understood, but central sensitisation is a key feature, leading to amplified pain processing. Current treatments, including analgesics, antidepressants, and exercise, often provide only modest relief, highlighting the need for novel approaches. Neuromodulation, which involves altering nerve activity through electrical or magnetic stimulation, has gained traction as a potential therapeutic strategy for various chronic pain states.1

A comprehensive review by Gallasch and Thieme, published in Schmerz, examined eight current non-invasive neuromodulation methods and their supporting evidence for chronic pain conditions.1 This review provides a framework for understanding how these diverse techniques, including transcutaneous electrical nerve stimulation (TENS), transcranial direct current stimulation (tDCS), and vagal nerve stimulation (VNS), might be applied. The authors also explored whether combining neuromodulation with behavioural or psychological pain therapy could enhance therapeutic outcomes, a significant consideration given the biopsychosocial nature of chronic pain.1

Understanding the Mechanism of Nerve Stimulation

The concept behind nerve stimulation for pain relief centres on modulating neural pathways involved in pain perception. Different neuromodulation techniques target distinct nerves or brain regions to achieve this. For instance, TENS works by delivering low-voltage electrical currents through electrodes placed on the skin, aiming to activate large-diameter afferent nerve fibres, which can inhibit pain signals via the gate control theory of pain. Other methods, like tDCS, apply weak direct currents to the scalp to modulate cortical excitability, influencing pain processing centres in the brain.1 Vagal nerve stimulation (VNS), specifically transcutaneous VNS (tVNS), represents another promising avenue because it can activate descending pain inhibitory pathways and modulate neurotransmitter release. The vagus nerve is a major component of the autonomic nervous system, playing a significant role in regulating inflammation, mood, and pain. Stimulating the vagus nerve can activate descending pain inhibitory pathways and modulate neurotransmitter release, potentially reducing central sensitisation. This mechanism is particularly relevant for conditions like fibromyalgia, where central sensitisation is a hallmark.1

Preclinical Evidence and Translational Potential

While direct human trials for tVNS in fibromyalgia are still in early stages, preclinical research offers compelling evidence for its potential. Yadav, Morris, and Conner, writing in JBMR Plus, demonstrated that transcutaneous vagal nerve stimulation improved post-traumatic osteoarthritis pain in mice.2 This study, while focused on osteoarthritis, provides significant insights into the analgesic effects of tVNS, showing significant reductions in pain-related behaviours in mice treated with tVNS compared to controls. The researchers observed significant reductions in pain-related behaviours in mice treated with tVNS compared to controls, suggesting a broader applicability of this technique to other chronic pain conditions.2

The translational potential of these preclinical findings to fibromyalgia is substantial. Both post-traumatic osteoarthritis pain and fibromyalgia involve elements of central sensitisation and neuroinflammation. If tVNS can effectively modulate these pathways in one chronic pain model, it stands to reason that similar mechanisms could be leveraged to alleviate fibromyalgia symptoms. The non-invasive nature of tVNS also makes it an attractive option, potentially reducing the risks associated with more invasive neuromodulation techniques.2

The Role of Wearable Technology

The practical application of non-invasive neuromodulation in clinical practice is heavily reliant on advancements in technology, particularly wearable devices. Caffrey, Jeong, and Del Rosario, in their review for the American Journal of Physical Medicine & Rehabilitation, highlighted the current state of wearable devices for bioelectrical stimulation in rehabilitation.3 These devices are making neuromodulation more accessible, user-friendly, and suitable for home use, which is critical for chronic conditions requiring long-term management.

Wearable devices for tVNS, for example, can be discreetly worn and operated by patients, allowing for consistent therapy without frequent clinic visits. This ease of use could significantly improve adherence, a common challenge in chronic pain management. The review noted that these devices often incorporate features like Bluetooth connectivity for data logging and remote monitoring by clinicians, enabling personalised adjustments to treatment parameters.3 Such technological integration could transform how neuromodulation therapies are delivered, moving them from specialised clinics into the daily lives of patients. The development of such devices also opens up possibilities for hypoglossal nerve stimulation for OSA, demonstrating the versatility of bioelectrical approaches.

Combining Neuromodulation with Behavioural Therapy

The Gallasch and Thieme review also emphasized the importance of integrating neuromodulation with behavioural or psychological pain therapy.1 Chronic pain, especially fibromyalgia, has significant psychological components, including anxiety, depression, and catastrophising, which can amplify pain perception. Combining a physical intervention like nerve stimulation with cognitive behavioural therapy (CBT) or mindfulness-based stress reduction (MBSR) could address both the physiological and psychological dimensions of pain. This multimodal approach aligns with current best practices in chronic pain management, which advocate for holistic, patient-centred care.1

For instance, neuromodulation might reduce the intensity of pain signals, making it easier for patients to engage in physical therapy or psychological interventions. Conversely, psychological therapies can help patients develop coping strategies, improve pain self-efficacy, and reduce the emotional distress associated with chronic pain, thereby enhancing the overall effectiveness of neuromodulation. This synergistic effect could lead to more sustained and meaningful improvements in quality of life for fibromyalgia patients. The ongoing discussion about adjunctive non-opioid therapies for musculoskeletal pain also highlights the need for comprehensive approaches.

Where the Evidence Falls Short (for now)

While the preclinical data and the general principles of neuromodulation are encouraging, the direct evidence for tVNS in fibromyalgia in human trials remains limited. The Gallasch and Thieme review, while comprehensive, primarily synthesises evidence across various chronic pain conditions, not exclusively fibromyalgia.1 This means that while the mechanisms are plausible, specific efficacy and safety profiles for fibromyalgia patients still require dedicated investigation. The review itself is a summary of existing evidence, not a primary clinical trial.1

Another caveat lies in the heterogeneity of fibromyalgia itself. Patients present with a wide range of symptoms and varying degrees of severity, making it challenging to design trials that capture a universally effective treatment. The optimal stimulation parameters (frequency, intensity, duration) for tVNS in fibromyalgia are also yet to be definitively established. These parameters can significantly influence therapeutic outcomes, and their individualisation will be key to successful implementation. The lack of large-scale, placebo-controlled trials specifically for tVNS in fibromyalgia means that while the concept is sound, the hard numbers are still pending. This is a common challenge in pain research, where even well-established drugs like cyclobenzaprine, which targets fibromyalgia pain by improving sleep, require careful patient selection. Cyclobenzaprine's mechanism highlights the complexity of addressing fibromyalgia symptoms.

The long-term durability of treatment effects also needs to be assessed. Chronic conditions like fibromyalgia require sustained relief, and it is not yet clear whether the benefits of tVNS persist over extended periods or if patients develop tolerance. While wearable devices enhance accessibility, ensuring proper patient training and adherence to stimulation protocols will be essential for real-world effectiveness. The potential for individual variability in response to neuromodulation also means that not all patients will benefit equally, necessitating careful patient selection and monitoring.

The Path Ahead

The current market of fibromyalgia treatment is ripe for innovation, and non-invasive neuromodulation, particularly tVNS, offers a compelling new direction. The preclinical evidence for its analgesic effects, coupled with advancements in wearable technology, positions it as a strong candidate for future clinical development. The emphasis on combining neuromodulation with behavioural therapies also reflects a more integrated and patient-centred approach to chronic pain management. The next steps involve rigorous, adequately powered clinical trials specifically targeting fibromyalgia patients to establish definitive efficacy, optimal treatment protocols, and long-term safety. Only then can nerve stimulation move from a promising concept to a standard of care for this challenging condition.

CLINICAL IMPLICATIONS

The prospect of non-invasive neuromodulation for fibromyalgia is genuinely intriguing, particularly for patients who have cycled through multiple pharmacological regimens with limited success. General practitioners and specialists alike are often left with few effective options, and the idea of a non-drug intervention that can modulate pain pathways directly is appealing. This could reduce reliance on polypharmacy and its associated side effects.

But clinicians should temper enthusiasm with a dose of realism. While the mechanistic rationale is sound, and preclinical data is encouraging, robust human trial data specifically for fibromyalgia remains sparse. The review by Gallasch and Thieme provides a useful overview of the field, but it is a synthesis, not a definitive trial. We need to see large, well-designed studies before this moves from 'promising' to 'prescribable'.

The integration of wearable technology is a critical enabler here. If patients can administer therapy at home, adherence will likely improve, and the burden on healthcare systems could decrease. But this also places a greater onus on patient education and remote monitoring. The Oxford Handbook of Clinical Medicine offers a concise reference for managing complex conditions, but the nuances of neuromodulation require dedicated training.

The real challenge will be identifying which fibromyalgia patients are most likely to benefit. Given the heterogeneity of the condition, a one-size-fits-all approach is unlikely to succeed. Future research must focus on biomarkers or clinical phenotypes that predict response to neuromodulation, ensuring that this therapy is directed to those who will truly gain from it, rather than becoming another expensive, ineffective option for the majority.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Gallasch L, Thieme K. Non-invasive neuromodulation for chronic pain: A review of eight current methods and the evidence. Schmerz. 2026.
2. 2. Yadav S, Morris L, Conner T. Transcutaneous vagal nerve stimulation improves post-traumatic osteoarthritis pain in mice. JBMR Plus. 2026.
3. 3. Caffrey JP, Jeong WJ, Del Rosario J. Wearable Devices for Bioelectrical Stimulation in Rehabilitation: Review of the Current State. Am J Phys Med Rehabil. 2026.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com